PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE-Reference-Cited by-同舟云学术

PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE

Published:2001-09 Issue:3 Volume:166 Page:851-855
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

RECKER FRANZ¹,KWIATKOWSKI MACIEJ K.¹,HUBER ANDREAS¹,STAMM BERNHARD¹,LEHMANN KURT¹,TSCHOLL RETO¹

Affiliation:

1. From the Clinic of Urology, Department of Laboratory Medicine and Institute of Pathology, Kantonsspital Aarau, Aarau, and Clinic of Urology, Kantonsspital Baden, Baden, Switzerland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference28 articles.

1. Prostate specific antigen: a decade of discovery—what we have learned and where we are going;Polascik;J Urol,1999

2. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men;Catalona;J Urol,1994

3. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease;Carter;JAMA,1992

4. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios;Oesterling;J Urol,1995

5. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen;Benson;J Urol, part 2,1992

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau);BJU International;2015-10-06

2. A “PSA Pyramid” for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening;European Urology;2015-10

3. Is further screening of men with baseline PSA < 1 ng ml−1worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau);International Journal of Cancer;2015-01-23

4. Stimuli-Responsive Reagent System for Enabling Microfluidic Immunoassays with Biomarker Purification and Enrichment;Bioconjugate Chemistry;2014-12-24

5. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau);World Journal of Urology;2014-10-31